This is ASCO week. The most anticipated oncology event of the year opens Thursday in Chicago and runs through June 2. Revolution Medicines’ plenary session on Saturday May 31 is the event the entire oncology community has been building toward since the Phase 3 topline readout on April 13. We know the headline numbers: 13.2 months median overall survival versus 6.7 months (HR 0.40, p<0.0001) in second-line pancreatic cancer. What we do not know: PFS data, detailed subgroup analyses, mature survival curves, safety details, and the full tumor response assessment. These are the data points that will determine whether daraxonrasib receives a broad or narrow label, how quickly it is adopted in clinical practice, and whether the commercial opportunity is at the low or high end of the $2 billion to $4 billion peak sales range. Truist projects an approval by end of Q3 under the CNPV program. Beyond Revolution, the ADC modality is on a historic run: Datroway was approved for first-line triple-negative breast cancer on May 22, just two weeks after Enhertu’s early breast cancer label expansion. Gilead received the first-ever HDV treatment approval. And the EU locked in its Critical Medicines Act to secure pharmaceutical supply chains.
ASCO 2026: The Most Important Oncology Event of the Year
ASCO 2026 opens Thursday May 29 at McCormick Place in Chicago and runs through June 2. The conference will feature hundreds of abstracts across oncology, with ADC data, checkpoint inhibitor combinations, cell therapy updates, and targeted therapy presentations drawing the most commercial and clinical interest. We will cover the most significant data in daily emails through the conference.
Beyond the Revolution plenary, ASCO presentations to watch include updates on the Keytruda franchise (Merck’s most important commercial asset heading into the 2028 patent cliff), checkpoint inhibitor combinations in new tumor types from BMS and Roche, Trodelvy data in additional indications from Gilead, and ADC pipeline presentations from the dozens of programs in clinical development across the industry. The conference historically serves as a catalyst for M&A discussions—practice-changing data presentations create acquisition targets, while disappointing readouts create partnership opportunities for companies seeking to restructure their development programs. With biopharma M&A running at approximately $93 billion through April and the deal pace showing no signs of slowing, ASCO could accelerate the second-half deal cycle.
The Plenary: Revolution Medicines on Saturday May 31
The plenary session is the headliner. Revolution Medicines will present full Phase 3 RASolute 302 data for daraxonrasib in second-line pancreatic ductal adenocarcinoma. Brian Wolpin, MD, of Dana-Farber Cancer Institute will present. The topline data released on April 13 showed a near-doubling of median overall survival: 13.2 months versus 6.7 months (HR 0.40, p<0.0001). That is the most compelling overall survival improvement in second-line pancreatic cancer in the history of the disease.
What the plenary needs to add beyond the topline:
PFS data has not yet been disclosed. A strong progression-free survival result would confirm that daraxonrasib both delays disease progression and extends survival, strengthening the approval case and the clinical positioning for oncologists.
Subgroup analyses will show whether daraxonrasib works equally well across RAS mutation subtypes (G12D, G12V, G12C, and others), in patients with prior immunotherapy, and across age groups, performance status, and geographic regions. A broadly positive subgroup analysis supports a wide label. A narrow result—activity concentrated in specific subgroups—would limit the addressable population.
Mature survival curves will show whether the separation between the treatment and control arms is sustained over time or begins to converge. The topline data came from the first interim analysis. Sustained curve separation is the strongest possible validation.
Safety details will provide the adverse event rates, dose modifications, treatment discontinuations, and quality-of-life data that oncologists need to make prescribing decisions. The topline described the drug as “generally well tolerated.” The plenary will put numbers behind that characterization.
Wolpin’s framing of the data—particularly around clinical significance and whether the results are practice-changing—will shape how the oncology community interprets the presentation. Pancreatic cancer has been one of the most intractable malignancies in oncology. A practice-changing result from a plenary presenter of Wolpin’s stature carries weight that extends beyond the numbers themselves.
The Filing Timeline
Truist projects an FDA approval by end of Q3 2026. If Revolution files under the CNPV program as planned, the 50-day Foundayo precedent suggests approval could come within weeks of filing. An NDA submission at or shortly after ASCO would put an August or September approval in range. The caveat remains: the CNPV program is operating without Commissioner Makary, who created it. Whether the program continues at the same pace under acting leadership is an open question that directly affects Revolution’s timeline.
Our Pro brief includes the detailed ASCO plenary preview with the specific data thresholds that would support a broad versus narrow label, the filing timeline model under CNPV versus standard NDA review, and the capital markets positioning heading into the presentation. [Details below.]
Datroway Approved for First-Line Triple-Negative Breast Cancer
What Happened: The FDA approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) on May 22 as a first-line treatment for patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor therapy. Datroway is a Trop-2-directed ADC.
Two ADC Label Expansions in Two Weeks
This is the second new ADC to receive a label expansion or approval in the early or first-line setting in two weeks, following Enhertu’s early breast cancer approval on May 16. Both drugs come from the AstraZeneca/Daiichi Sankyo partnership. Both target breast cancer subtypes. The pace of ADC label expansions in 2026 is unprecedented.
The TNBC market has historically been among the hardest to treat in oncology. Triple-negative breast cancer lacks the hormone receptors and HER2 expression that make other breast cancer subtypes targetable by existing therapies. For patients who cannot receive checkpoint inhibitor immunotherapy—because their tumors lack PD-L1 expression or because of contraindications—treatment options have been limited to chemotherapy. Datroway fills a critical gap by providing a targeted therapy for a population that has lacked one.
What This Means for the ADC Trajectory
The ADC modality is moving from late-line salvage therapy to frontline standard of care at a pace that mirrors the checkpoint inhibitor trajectory from 2015 to 2020. Enhertu in early (curative-intent) breast cancer. Datroway in first-line TNBC. Merck’s sac-TMT in endometrial cancer. Each expansion moves ADCs earlier in the treatment algorithm, where patient volumes are larger and treatment durations are longer. For Daiichi Sankyo’s $14.6 billion oncology revenue target by 2030, these label expansions are essential building blocks.
Gilead Hepcludex Approved as First-Ever HDV Treatment in the U.S.
What Happened: The FDA granted accelerated approval for Gilead’s Hepcludex (bulevirtide) on May 23 for adults with chronic hepatitis delta virus infection, making it the first and only approved treatment for HDV in the United States. GILD shares rose 3%.
Why First-Ever Matters
Hepatitis delta virus is the most severe form of viral hepatitis, affecting an estimated 12 million to 72 million people globally. HDV requires co-infection with hepatitis B virus to replicate and causes accelerated liver damage, cirrhosis, and liver failure at higher rates than hepatitis B alone. Until Hepcludex, there was no approved therapy specifically targeting HDV—patients received supportive care and hepatitis B treatment, but nothing that addressed the delta virus directly.
The accelerated approval pathway means Gilead will need to confirm the clinical benefit through post-marketing studies. But for HDV patients who have waited decades for a targeted treatment, the approval is transformative. The disease has been identified since 1977 and has gone nearly fifty years without a single approved therapy in the United States.
The approval adds another franchise to Gilead’s hepatitis and HIV portfolio, complementing the company’s ongoing diversification into oncology (Trodelvy, Tubulis ADC platform) and cell therapy (Arcellx CAR-T). Gilead has deployed approximately $15 billion in M&A in 2026 to build its oncology pipeline; the Hepcludex approval ensures the virology foundation that built the company remains productive and commercially relevant alongside the newer therapeutic areas. The estimated patient population of 12 million to 72 million globally represents a potentially large commercial opportunity, though the wide range reflects the challenges of diagnosing HDV, which requires specific testing beyond standard hepatitis B screening.
EU Locks In Critical Medicines Act
What Happened: The European Parliament and EU member states reached a provisional agreement on the Critical Medicines Act (CMA) on May 22. The legislation is designed to strengthen medicine supply chains, reduce dependency on non-EU API and raw material sources, and establish strategic reserves of critical medicines.
Why This Matters
The CMA comes as the Iran war continues to disrupt pharmaceutical trade routes and global API supply chains. The Strait of Hormuz disruption has driven supplier price increases (Evonik +15%), Indian API rerouting at dramatically higher costs, and growing concerns about generic drug shortages in multiple countries. The EU is responding with legislation that mirrors the onshoring incentives the United States has pursued through the Section 232 tariff framework, though through legislative mandates and strategic reserve requirements rather than tariff threats.
The CMA establishes several key mechanisms: identification of critical medicines and APIs that require supply chain security measures, requirements for strategic stockpiling of essential medicines, and incentives for domestic or allied-nation manufacturing of critical inputs. For pharmaceutical companies operating in Europe, the CMA creates new compliance requirements around supply chain transparency and may influence sourcing decisions for API and raw material procurement.
Separately, EFPIA (the European pharmaceutical industry association) warned that the U.S. Most Favored Nation pricing policy could widen disparities in access to new medicines across Europe. The concern is that as U.S. companies agree to lower Medicaid prices under MFN deals, they may delay or reduce launches in European markets where prices are already lower, creating access gaps for European patients. The warning highlights a dynamic that many industry observers have noted: MFN pricing that references European prices as a floor could make European launches less commercially attractive, potentially reducing the innovation access that European patients have historically benefited from.
The convergence of the CMA and the EFPIA warning illustrates the global policy tension: governments are simultaneously trying to secure pharmaceutical supply chains (requiring domestic manufacturing investment) and lower drug prices (compressing the margins that fund that investment). The two objectives are structurally in tension, and pharmaceutical companies must navigate both simultaneously.
Strategic Themes
1. Saturday May 31 Is the Single Most Important Day on the 2026 Oncology Calendar
Revolution Medicines’ plenary presentation will either confirm daraxonrasib as a practice-changing therapy for pancreatic cancer or raise questions about the breadth of its applicability. The detailed data—PFS, subgroups, survival curves, safety—will determine the label scope, the speed of clinical adoption, and the commercial trajectory. For pancreatic cancer patients who have had essentially no effective second-line treatment options, this is the most significant therapeutic advance in a generation. For the oncology industry, it is the dataset that defines whether RAS-targeted therapy fulfills the promise that has driven years of drug development investment against one of the most common oncogenic drivers in solid tumors. RAS mutations drive more than 90% of pancreatic cancers and significant portions of lung and colorectal cancers. If the plenary data confirm a broad, clean benefit across subgroups, the implications extend well beyond pancreatic cancer to every RAS-driven malignancy.
2. ADCs in the First-Line Setting Are Now a Reality, Not a Projection
Two first-line or curative-setting ADC approvals in two weeks. Both from AstraZeneca/Daiichi Sankyo. The modality’s trajectory from late-line to frontline is accelerating faster than most industry observers anticipated. For companies with ADC programs in development—Merck (sac-TMT), Gilead (Tubulis platform), and dozens of clinical-stage biotechs—the validated path from metastatic to first-line gives every program a roadmap for label expansion that dramatically increases the addressable market.
3. Gilead’s First-Ever HDV Approval Adds a New Franchise to an Expanding Portfolio
Hepcludex addresses a disease that has had no treatment for decades. The first-ever approval carries both commercial value and reputational significance for Gilead’s virology franchise. Combined with the company’s $15 billion in 2026 oncology M&A, Gilead is executing a multi-franchise growth strategy that maintains its virology foundation while building aggressively in oncology and cell therapy.
4. The EU Critical Medicines Act Joins the U.S. Section 232 Framework in the Global Supply Chain Restructuring
Both the United States and the European Union are now implementing legislative or regulatory frameworks to secure pharmaceutical supply chains through domestic manufacturing incentives. The Iran war has accelerated the urgency. The EFPIA warning about MFN pricing effects on European access adds a complication: the policies designed to lower prices may inadvertently reduce the launches and investment that supply chain security depends on. For multinational pharma companies, navigating these dual pressures—onshore more, charge less—is becoming the defining strategic challenge of the decade.
Frequently Asked Questions
When is ASCO?
May 29 through June 2 in Chicago. Revolution Medicines presents full Phase 3 RASolute 302 data in a plenary session on Saturday May 31. Brian Wolpin of Dana-Farber is presenting.
What do we know about the Revolution data?
Topline: 13.2 months median OS versus 6.7 months (HR 0.40, p<0.0001) in second-line pancreatic cancer. The plenary will add PFS data, subgroup analyses, mature survival curves, and detailed safety data. Truist projects an approval by end of Q3 under the CNPV program.
What is Datroway?
Datopotamab deruxtecan, a Trop-2-directed ADC from AstraZeneca/Daiichi Sankyo. Approved May 22 for first-line metastatic TNBC in patients ineligible for checkpoint inhibitor therapy. The second ADC label expansion in the first-line or curative setting in two weeks.
What is Hepcludex?
Bulevirtide, approved by the FDA on May 23 as the first and only treatment for chronic hepatitis delta virus in the United States. HDV is the most severe form of viral hepatitis, affecting an estimated 12 million to 72 million people globally. Gilead received accelerated approval.
What is the EU Critical Medicines Act?
A legislative framework to strengthen European medicine supply chains, reduce dependency on non-EU API sources, and establish strategic reserves. The agreement was reached May 22. It mirrors the supply chain security objectives of the U.S. Section 232 tariff framework.
When could Revolution be approved?
Truist projects end of Q3 2026 if Revolution files under the CNPV program. The 50-day Foundayo precedent suggests approval could come within weeks of filing. An NDA submission at or shortly after ASCO would put August or September in range.
What about the Commerce Section 232 device report?
Still expected late May. The report will inform the tariff framework for medical devices. Medtech companies including Medtronic, Boston Scientific, Abbott, Intuitive Surgical, and Stryker are watching for the implications.
When does the Medicare GLP-1 Bridge program launch?
July 1. The program provides GLP-1 access for Medicare Part D beneficiaries at a $50 per month copay. Operational readiness will determine initial enrollment volume. Five weeks out.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
ASCO Plenary Preview. We detail the five data elements Revolution needs to deliver on Saturday—PFS, subgroups, survival curves, safety, and presenter framing—and what each result would mean for label scope, clinical adoption speed, and the commercial trajectory between the low and high ends of the peak sales range.
ADC Momentum. We track the two first-line/curative-setting ADC approvals in two weeks, analyze what the AstraZeneca/Daiichi Sankyo dominance means for Daiichi Sankyo’s $14.6B oncology target, and assess which pipeline ADC programs are best positioned to pursue their own first-line label expansions.
Revolution Filing Timeline. We model the CNPV path from ASCO presentation to NDA filing to potential Q3 approval, assess the risk that the FDA leadership transition introduces delays, and lay out the revenue implications of an August 2026 versus mid-2027 approval scenario.
Plus: Gilead HDV franchise analysis, EU CMA supply chain implications, EFPIA MFN warning assessment, Medicare Bridge readiness, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
